LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Wheaton Acquires Bioreactor Flask Line from Wilson Wolf

By LabMedica International staff writers
Posted on 25 Jul 2012
Wheaton Industries (Millville, NJ, USA) has acquired the CELLine bioreactor flask line for antibody and protein production from Wilson Wolf Manufacturing Corp. (New Brighton, MN, USA).

Wheaton has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corp. Wheaton has also entered into a long term strategic partnership with Wilson Wolf Manufacturing for additional product development in high density cell culture devices for the production of concentrated, cell secreted products.

CELLine flasks are easy to implement and are known worldwide for small-scale suspension and adherent cultures. The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.

The flasks enhance small-scale bioproduction for antibody and protein generation. Conventional in vivo or in vitro cell culture methods can be labor-intensive, result in low cell density, and require significant purification. The CELLine flasks address these three areas of limitation in a single use, repeatable technology. CELLine flasks are ready-to-use and disposable, and generate high cell density and high product concentration, while considerably reducing culture and processing time.

“We are excited to bring this innovative, high growth technology to Wheaton and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing Wheaton portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, president of Wheaton. “We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.

Related Links:

Wheaton Industries
Wilson Wolf Manufacturing


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Thyroid Test
Anti-Thyroid EIA Test

Channels

Molecular Diagnostics

view channel
Image: Researchers identified blood-based genomic signatures characteristic of inflammatory breast cancer (photo courtesy of Shutterstock)

Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring

Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
ADLM